Elkhorn Partners Limited Partnership Purchases 3,400 Shares of Pfizer Inc. (NYSE:PFE)

Elkhorn Partners Limited Partnership boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 55.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,500 shares of the biopharmaceutical company’s stock after acquiring an additional 3,400 shares during the quarter. Pfizer makes up approximately 0.2% of Elkhorn Partners Limited Partnership’s portfolio, making the stock its 16th largest holding. Elkhorn Partners Limited Partnership’s holdings in Pfizer were worth $252,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. PSI Advisors LLC raised its stake in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its position in shares of Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. lifted its stake in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 391 shares during the last quarter. Lipe & Dalton boosted its holdings in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 400 shares during the period. Finally, Oliver Luxxe Assets LLC grew its stake in Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 401 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.4 %

NYSE PFE opened at $21.89 on Monday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock’s 50 day moving average is $25.25 and its two-hundred day moving average is $26.38. The company has a market capitalization of $124.14 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the business earned $0.10 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PFE shares. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group lowered their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $31.07.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.